论文部分内容阅读
目的探讨不同急诊PCI术前负荷剂量阿托伐他汀对于急性ST段抬高型心肌梗死患者治疗的中期疗效的影响。方法选择2013年5月—2015年3月期间在南阳市第一人民医院治疗的急性ST段抬高型心肌梗死患者60例为研究对象,将其随机均分为两组,两组采用不同剂量的阿托伐他汀的用药方案,对比两组患者的中期治疗效果。结果观察组患者的hs-CRP、MMP-9、BNP均显著低于对照组,两组对比存在显著性差异(P<0.05);但两组的LVEDD、ALT和LVEF对比无显著性差异(P>0.05)。结论阿托伐他汀能有效控制急性ST段抬高型心肌梗死患者的炎症,改善患者的心脏心室收缩功能,安全性好,具有重要的临床意义,值得大力推广。
Objective To investigate the effect of different doses of atorvastatin in patients with acute ST-segment elevation myocardial infarction on the medium-term efficacy of different emergency PCI. Methods Sixty patients with acute ST-segment elevation myocardial infarction who were treated in Nanyang First People’s Hospital from May 2013 to March 2015 were selected and divided into two groups randomly. The two groups were given different doses Of atorvastatin medication regimen, comparing the two groups of patients in the medium-term treatment. Results The levels of hs-CRP, MMP-9 and BNP in observation group were significantly lower than those in control group, there was significant difference between the two groups (P <0.05); however, there was no significant difference in LVEDD, ALT and LVEF between two groups > 0.05). Conclusions Atorvastatin can effectively control the inflammation in patients with acute ST-segment elevation myocardial infarction and improve the cardiac ventricular systolic function in patients with good safety. It is of great clinical significance and worth to be popularized.